Ceftizoxime (CAS 68401-81-0)

Ceftizoxime, a third-generation cephalosporin antibiotic, is widely used in microbiological research for its effective bactericidal action, specifically targeting a broad range of Gram-positive and Gram-negative bacteria. Its mechanism of action involves the inhibition of bacterial cell wall synthesis by binding to and inactivating penicillin-binding proteins (PBPs). These proteins are essential for maintaining the structural integrity of the bacterial cell wall; their inactivation leads to the disruption of cell wall synthesis, resulting in bacterial cell lysis. Ceftizoxime is particularly valued in research settings for its stability against beta-lactamases, enzymes produced by bacteria that degrade many other beta-lactam antibiotics. This property makes it an excellent tool for studying antibiotic resistance mechanisms, especially in pathogens that express extended-spectrum beta-lactamases (ESBLs). Additionally, Ceftizoxime′s ability to penetrate bacterial cells efficiently allows for detailed studies on the kinetics and dynamics of antibiotic action within different bacterial populations. Researchers also utilize this chemical to examine the interactions between antibiotics and bacterial membranes, providing insights into how structural modifications in cephalosporins affect their efficacy and resistance profiles. Through these applications, Ceftizoxime aids in advancing our understanding of microbial resistance, guiding the development of new strategies to combat infectious diseases in research environments.